These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25034010)

  • 1. The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.
    Moss L; Wagner D; Kanaoka E; Olson K; Yueh YL; Bowers GD
    Xenobiotica; 2015 Jan; 45(1):60-70. PubMed ID: 25034010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
    Castellino S; Moss L; Wagner D; Borland J; Song I; Chen S; Lou Y; Min SS; Goljer I; Culp A; Piscitelli SC; Savina PM
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3536-46. PubMed ID: 23669385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
    Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.
    Zhang J; Hayes S; Sadler BM; Minto I; Brandt J; Piscitelli S; Min S; Song IH
    Br J Clin Pharmacol; 2015 Sep; 80(3):502-14. PubMed ID: 25819132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
    Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
    Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.
    Zhu M; Whigan DB; Chang SY; Dockens RC
    Drug Metab Dispos; 2008 Jan; 36(1):24-35. PubMed ID: 17908924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects.
    Patel P; Song I; Borland J; Chen S; Peppercorn A; Wajima T; Funaki T; Fujita N; Hughes J; Piscitelli S
    Antivir Ther; 2014; 19(3):229-33. PubMed ID: 24275098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
    Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
    Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
    Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
    Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.
    Radulovic LL; Türck D; von Hodenberg A; Vollmer KO; McNally WP; DeHart PD; Hanson BJ; Bockbrader HN; Chang T
    Drug Metab Dispos; 1995 Apr; 23(4):441-8. PubMed ID: 7600909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
    Emary WB; Toren PC; Mathews B; Huh K
    Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.
    Schalkwijk S; Greupink R; Colbers AP; Wouterse AC; Verweij VG; van Drongelen J; Teulen M; van den Oetelaar D; Burger DM; Russel FG
    J Antimicrob Chemother; 2016 Feb; 71(2):480-3. PubMed ID: 26538508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.